FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - December 5, 2025 40 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Mom Fights Second Round Of Breast Cancer — Weeks Later, Her... September 13, 2019 Adding Tremelimumab to Durvalumab and Chemotherapy Provides Survival Benefit for Patients... November 15, 2022 Physical Activity May Lessen the Effects of Chemobrain, Study Finds August 26, 2021 Gynaecological Cancers: Immunotherapy and Novel Targeted Drug Appear Beneficial in Group... September 13, 2024 Load more HOT NEWS Teacher on Leave for Breast Cancer Treatment Forced to Pay for... Surgeons Use Tissue From Cancer Survivor’s Love Handles For Rare Type... Research with integrity – the importance of communication EMA Recommends Extension of Indications for Glofitamab
